Copaxone is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
Craig Wheeler, president and CEO of Momenta, said: “Advancing the M356 program for the development of a generic version of Copaxone is one of Momenta’s top priorities, and we are pleased that the abbreviated new drug application (ANDA) has been accepted for review.”